Investor update

OptiBiotix Health PLC

10 May 2024

 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

10 May 2024

Investor update

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease, diabetes and skincare, announces that Stephen O'Hara, CEO of OptiBiotix will provide a live presentation to investors via the Investor Meet Company platform on Monday, 20 May 2024 at 2pm BST.

Stephen will use this opportunity to update investors on OptiBiotix's commercial progress and opportunity pipeline, and the Company's progress in e-commerce, and in the USA, and Asia, and plans for the launch of second generation products.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet OptiBiotix.

To register for the presentation, please use this link: https://www.investormeetcompany.com/optibiotix-health-plc/register-investor

Investors who already follow OptiBiotix on the Investor Meet Company platform will automatically be invited.

For further information, please contact:

OptiBiotix Health plc		www.optibiotix.com
Neil Davidson, Chairman	Contact via Walbrook below
Stephen O'Hara, Chief Executive
Peterhouse Capital Limited (Broker)		Tel: [phone]
Duncan Vasey / Lucy Williams
Walbrook PR Ltd		Mob: [phone]
Anna Dunphy

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

END